Bioactivity of a 29-Kilodalton Insulin-Like Growth Factor Binding Protein-3 Fragment Present in Excess in Chronic Renal Failure Serum
- 1 September 1997
- journal article
- Published by Springer Nature in Pediatric Research
- Vol. 42 (3) , 335-341
- https://doi.org/10.1203/00006450-199709000-00014
Abstract
Children with chronic renal failure (CRF) have normal or high serum levels of GH, IGF-I, and IGF-II. Despite this, the serum of CRF patients has low IGF bioactivity, which may contribute to CRF growth failure. Recent studies suggest that excess IGF binding proteins (IGFBPs) in the ≈35-kD fractions of CRF serum contribute to this low IGF bioactivity. This report characterizes a 29-kD form of IGFBP-3, IGFBP-329, which accumulates in the ≈35-kD fractions of CRF serum and peritoneal dialysate. Deglycosylation and[125I]IGF ligand blot studies show that IGFBP-329 is a glycosylated IGFBP-3 fragment with low affinity for IGF peptides. Using an IGFBP-3 antibody column, IGFBP-329 was purified to homogeneity from the≈35-kD fractions of peritoneal dialysate from children with CRF. Compared with native IGFBP-3, pure IGFBP-329 has a 4-10-fold lower affinity for IGF-II and a 200-fold lower affinity for IGF-I. Consistent with the binding data, IGFBP-329 inhibited IGF-II-stimulated thymidine incorporation in chondrosarcoma cells, but was a less potent inhibitor than native IGFBP-3; also, native IGFBP-3 clearly inhibited IGF-I-stimulated thymidine incorporation in chondrosarcoma cells and potentiated IGF-I-stimulated aminoisobutyric acid uptake in bovine fibroblasts, but higher concentrations of IGFBP-329 had no effect on these IGF-I actions. Thus, the 29-kD IGFBP-3 form that accumulates in CRF serum and extravascular spaces is an IGFBP-3 fragment that may modulate IGF-II, but not IGF-I, effects on target tissues. Whether IGFBP-329 plays any role in the growth failure of children with CRF remains to be determined.Keywords
This publication has 47 references indexed in Scilit:
- Modulation of growth factors by growth hormone in children with chronic renal failureKidney International, 1997
- Characterization of insulin-like growth factors and their binding proteins in peritoneal dialysatePediatric Nephrology, 1996
- Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in ChildhoodJournal of Clinical Endocrinology & Metabolism, 1995
- Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasmaEndocrinology, 1994
- IGFs: function and clinical importance 2 The regulation of osteoblast function by hormones and cytokines with special reference to insulin‐like growth factors and their binding proteinsJournal of Internal Medicine, 1993
- Measurement and characterization of insulin-like growth factor binding protein-3 in human biological fluids: discrepancies between radioimmunoassay and ligand blottingEndocrinology, 1992
- Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failureThe Lancet, 1991
- Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: Control of IGF signalling to bone cells by IGFBP-3-specific proteolysis?Biochemical and Biophysical Research Communications, 1991
- Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal diseaseThe Journal of Pediatrics, 1990
- Binding proteins for the insulin-like growth factors: Structure, regulation and functionProgress in Growth Factor Research, 1989